[go: up one dir, main page]

EA201300946A1 - Асимметричные мочевины и их медицинское применение - Google Patents

Асимметричные мочевины и их медицинское применение

Info

Publication number
EA201300946A1
EA201300946A1 EA201300946A EA201300946A EA201300946A1 EA 201300946 A1 EA201300946 A1 EA 201300946A1 EA 201300946 A EA201300946 A EA 201300946A EA 201300946 A EA201300946 A EA 201300946A EA 201300946 A1 EA201300946 A1 EA 201300946A1
Authority
EA
Eurasian Patent Office
Prior art keywords
medical application
asymmetric urea
compounds
asymmetric
urea
Prior art date
Application number
EA201300946A
Other languages
English (en)
Other versions
EA027374B1 (ru
Inventor
Сильвина Гарсия Рубио
Клаудио Пьетра
Клаудио Джулиано
Чжиган Ли
Original Assignee
Хельсинн Хелскэа Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хельсинн Хелскэа Са filed Critical Хельсинн Хелскэа Са
Publication of EA201300946A1 publication Critical patent/EA201300946A1/ru
Publication of EA027374B1 publication Critical patent/EA027374B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Раскрываются соединения, композиции и способы предотвращения и/или лечения заболеваний, которые патофизиологически опосредуются грелиновым рецептором. Соединения имеют общую формулу (I)
EA201300946A 2011-02-25 2012-02-23 Асимметричные мочевины и их медицинское применение EA027374B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2011/000298 WO2012113103A1 (en) 2011-02-25 2011-02-25 Asymmetric ureas and medical uses thereof
US201161466070P 2011-03-22 2011-03-22
PCT/US2012/026315 WO2012116176A2 (en) 2011-02-25 2012-02-23 Asymmetric ureas and medical uses thereof

Publications (2)

Publication Number Publication Date
EA201300946A1 true EA201300946A1 (ru) 2014-06-30
EA027374B1 EA027374B1 (ru) 2017-07-31

Family

ID=46719417

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300946A EA027374B1 (ru) 2011-02-25 2012-02-23 Асимметричные мочевины и их медицинское применение

Country Status (41)

Country Link
US (3) US8658797B2 (ru)
EP (1) EP2678017B1 (ru)
JP (1) JP6077468B2 (ru)
KR (2) KR101907573B1 (ru)
CN (2) CN103874492B (ru)
AP (1) AP3768A (ru)
AR (1) AR085398A1 (ru)
AU (1) AU2012220531B2 (ru)
BR (1) BR112013021566B1 (ru)
CA (1) CA2820767C (ru)
CL (1) CL2013002412A1 (ru)
CO (1) CO6771450A2 (ru)
CY (1) CY1118947T1 (ru)
DK (1) DK2678017T3 (ru)
DO (1) DOP2013000195A (ru)
EA (1) EA027374B1 (ru)
EC (1) ECSP13012893A (ru)
ES (1) ES2628386T3 (ru)
GE (1) GEP20156319B (ru)
HR (1) HRP20170997T1 (ru)
HU (1) HUE035039T2 (ru)
IL (1) IL227941A (ru)
LT (1) LT2678017T (ru)
MA (1) MA34968B1 (ru)
ME (1) ME02845B (ru)
MX (1) MX347587B (ru)
MY (1) MY164354A (ru)
NI (1) NI201300070A (ru)
PE (1) PE20141000A1 (ru)
PH (1) PH12013501757A1 (ru)
PL (1) PL2678017T3 (ru)
PT (1) PT2678017T (ru)
RS (1) RS56033B1 (ru)
SG (1) SG192138A1 (ru)
SI (1) SI2678017T1 (ru)
SM (1) SMT201700407T1 (ru)
TN (1) TN2013000346A1 (ru)
TW (1) TWI579273B (ru)
UA (1) UA113510C2 (ru)
WO (2) WO2012113103A1 (ru)
ZA (1) ZA201307071B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113103A1 (en) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
CN105073133B (zh) 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
TWI703130B (zh) 2014-03-07 2020-09-01 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
RU2686317C2 (ru) * 2015-04-24 2019-04-25 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Замещенные 1,2,5-триметил- и 2,2,6,6-тетраметил-4-аминопиперидины, обладающие антиишемическим действием
KR102640774B1 (ko) 2016-03-22 2024-02-26 헬신 헬쓰케어 에스.에이. 벤젠술포닐-비대칭 우레아 및 그의 의학적 용도
JPWO2019031471A1 (ja) * 2017-08-07 2020-11-26 国立大学法人広島大学 脂肪性肝疾患の治療剤及び肥満症の治療剤
WO2019040107A1 (en) 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES
EP3672960A2 (en) 2017-08-21 2020-07-01 Acadia Pharmaceuticals Inc. Compounds, salts thereof and their use for the treatment of diseases
MA51132A (fr) 2017-12-11 2020-10-21 Helsinn Healthcare Sa Sel de fumarate de l'urée (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phényl)-2,2,2-trifluoroéthyl)-1-méthyl-1-(1-méthylpipéridin-4-yl), procédés de préparation et utilisations de celui-ci
EP3542799A1 (en) 2018-03-22 2019-09-25 Helsinn Healthcare SA New centrally-active ghrelin agonist and medical uses thereof
BR112023018277A2 (pt) 2021-03-10 2024-01-16 Jnana Therapeutics Inc Inibidores de pequenas moléculas da função de slc6a19 de mamíferos
US20250205216A2 (en) 2021-06-02 2025-06-26 Helsinn Healthcare Sa Piperidine Urea Derivatives for Use as Inotropic Agents
WO2023048762A1 (en) * 2021-09-22 2023-03-30 Duke University Compositions for the treatment of food and chemical addiction and methods of making and using same
WO2024158862A1 (en) * 2023-01-25 2024-08-02 University Of North Texas Health Science Center Thiourea antioxcompounds with neuroprotective activity

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5285174A (en) * 1976-01-05 1977-07-15 Yoshitomi Pharmaceut Ind Ltd Novel urea or thiourea derivatives
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU3785597A (en) 1996-08-14 1998-03-06 Takeda Chemical Industries Ltd. Cyclic urea compounds, their production and use as herbicides
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
DK1787984T3 (en) * 2000-03-06 2017-01-30 Acadia Pharm Inc AZACYCLIC COMPOUNDS FOR USING THE TREATMENT OF SEROTON-RELATED DISEASES
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US20030022891A1 (en) * 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
JP2004520423A (ja) 2001-03-01 2004-07-08 アストラゼネカ・アクチエボラーグ Ｃｃｒ５モジュレーターとしてのｎ−ピペリジニル化合物
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US6673829B2 (en) * 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
US7414057B2 (en) * 2002-09-11 2008-08-19 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
JPWO2004046110A1 (ja) 2002-11-15 2006-03-16 アステラス製薬株式会社 メラニン凝集ホルモン受容体拮抗剤
CN1839116B (zh) * 2003-06-30 2010-05-26 住友化学株式会社 不对称脲化合物和通过用其作催化剂的不对称共轭加成反应制备不对称化合物的方法
US7115767B2 (en) * 2003-07-18 2006-10-03 Abbott Laboratories Tetraline derivatives as ghrelin receptor modulators
DE602005002251D1 (de) * 2004-02-10 2007-10-11 Janssen Pharmaceutica Nv Pyridazinonharnstoffe als antagonisten von a4-integrinen
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0401971D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
EP1784390A2 (en) * 2004-08-13 2007-05-16 Amgen Inc. Substituted benzofused heterocycles
EP1804785A2 (en) * 2004-10-27 2007-07-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
US20080306055A1 (en) 2004-12-21 2008-12-11 Astrazeneca Ab Heterocyclic Mchr1 Antagonists And Their Use In Therapy
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
WO2007029086A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
EA200801243A1 (ru) * 2005-11-01 2008-10-30 Транстек Фарма Фармацевтическое применение замещенных амидов
AR058277A1 (es) * 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
US20090253673A1 (en) 2006-07-12 2009-10-08 Min Ge Substituted Pyrazoles as Ghrelin Receptor Antagonists
JP2008042298A (ja) 2006-08-02 2008-02-21 Olympus Corp 固体撮像装置
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
WO2008141057A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
GB0710863D0 (en) * 2007-06-06 2007-07-18 Glaxo Group Ltd Novel compounds
GB0710865D0 (en) 2007-06-06 2007-07-18 Glaxo Group Ltd Novel compounds
US20110098322A1 (en) 2007-08-06 2011-04-28 The Regents Of The University Of California Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase
AU2008302079A1 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. Co-administration of pimavanserin with other agents
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
WO2009092293A1 (en) 2008-01-18 2009-07-30 Shanghai Targetdrug Co., Ltd. Pyrollidine-based compounds
WO2009089659A1 (en) 2008-01-18 2009-07-23 Shanghai Targetdrug Co., Ltd. Pyrollidine-based compounds
USRE48334E1 (en) * 2008-09-19 2020-12-01 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
WO2010111353A1 (en) * 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2011060397A1 (en) * 2009-11-16 2011-05-19 Schering Corporation Substituted amino heterocycles useful as hiv antagonists
WO2012113103A1 (en) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof

Also Published As

Publication number Publication date
SI2678017T1 (sl) 2017-07-31
CL2013002412A1 (es) 2014-02-07
IL227941A0 (en) 2013-09-30
BR112013021566B1 (pt) 2020-11-17
EA027374B1 (ru) 2017-07-31
TN2013000346A1 (en) 2015-01-20
US10407390B2 (en) 2019-09-10
KR101907573B1 (ko) 2018-10-15
MY164354A (en) 2017-12-15
TWI579273B (zh) 2017-04-21
PH12013501757A1 (en) 2013-10-14
MX2013006974A (es) 2013-10-07
EP2678017A2 (en) 2014-01-01
WO2012113103A1 (en) 2012-08-30
JP6077468B2 (ja) 2017-02-08
AP3768A (en) 2016-08-31
AU2012220531B2 (en) 2017-02-23
LT2678017T (lt) 2017-06-26
US20180044293A1 (en) 2018-02-15
PT2678017T (pt) 2017-06-26
AR085398A1 (es) 2013-09-25
CA2820767C (en) 2019-06-25
AU2012220531A1 (en) 2013-09-26
EP2678017B1 (en) 2017-04-05
AP2013007123A0 (en) 2013-09-30
IL227941A (en) 2017-10-31
ZA201307071B (en) 2014-06-25
CO6771450A2 (es) 2013-10-15
BR112013021566A2 (pt) 2016-11-08
MX347587B (es) 2017-05-03
MA34968B1 (fr) 2014-03-01
WO2012116176A2 (en) 2012-08-30
WO2012116176A3 (en) 2014-04-24
SMT201700407T1 (it) 2017-09-07
PL2678017T3 (pl) 2017-09-29
US8658797B2 (en) 2014-02-25
PE20141000A1 (es) 2014-08-09
US20120220629A1 (en) 2012-08-30
TW201245151A (en) 2012-11-16
ECSP13012893A (es) 2013-11-29
CY1118947T1 (el) 2018-01-10
EP2678017A4 (en) 2015-05-20
ME02845B (me) 2018-01-20
CN103874492B (zh) 2016-12-07
KR20140014186A (ko) 2014-02-05
DK2678017T3 (en) 2017-07-24
US9751836B2 (en) 2017-09-05
ES2628386T3 (es) 2017-08-02
JP2014518543A (ja) 2014-07-31
SG192138A1 (en) 2013-08-30
RS56033B1 (sr) 2017-09-29
CA2820767A1 (en) 2012-08-30
CN106995403B (zh) 2020-04-24
US20140121210A1 (en) 2014-05-01
UA113510C2 (uk) 2017-02-10
KR20180075703A (ko) 2018-07-04
HRP20170997T1 (hr) 2017-10-06
CN106995403A (zh) 2017-08-01
NI201300070A (es) 2014-03-11
HUE035039T2 (en) 2018-05-02
NZ615283A (en) 2015-09-25
GEP20156319B (en) 2015-07-10
CN103874492A (zh) 2014-06-18
DOP2013000195A (es) 2014-12-15

Similar Documents

Publication Publication Date Title
EA201300946A1 (ru) Асимметричные мочевины и их медицинское применение
UA115136C2 (uk) Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1
CY1122278T1 (el) Αντι il-36r αντισωματα
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201590292A1 (ru) Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
EA201201357A1 (ru) Антитела к cd40
EA201590534A1 (ru) Новые бициклические производные
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201290642A1 (ru) Соединения и способы
EA201171063A1 (ru) Фармацевтические составы олмесартана
EA201490846A1 (ru) Новые производные арилхинолина
EA201591024A1 (ru) Димерные соединения
EA201691141A1 (ru) Соединения против ccr6
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
PH12016501483A1 (en) P-substituted asymmetric ureas and medical uses thereof
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201491581A1 (ru) Везикулярные композиции
DK3725810T3 (da) Kombinationterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
EA201501177A1 (ru) Фармацевтические композиции
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
TH171895A (th) P-ซับสทิทิวเตดอะซิมเมทริกยูเรีย และการใช้ทางการแพทย์ของมัน